Axsome Therapeutics, Inc.
AXSM NASDAQHealthcare ★★★★★Latest Earnings
Date
Aug 10, 2026
ET
EPS Est.
-0.89
EPS Actual
-0.99
Revenue Est.
$221.1M
Revenue Actual
$216.4M
Next Earnings Report
Date
Nov 2, 2026 · Mon
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
-0.49
Revenue Est.
$258.1M
Company Overview
Axsome Therapeutics, Inc. (ticker AXSM) is listed on NASDAQ with a market cap of about $10.69B. Its next earnings report (FY2026 Q3) is expected on Nov 2, 2026 (ET), Pre-market, with consensus EPS of -0.49. In the last 15 reported quarters, EPS beat consensus estimates 5 times.
Actual EPS TrendRecently15Term · Feb 27, 2023 → Aug 10, 2026
Feb 27, 2023Range: -2.08 ~ -0.22Aug 10, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 10, 2026 | -- | -0.89 | -0.99 | $221.1M | $216.4M |
| May 4, 2026 | -- | -0.85 | Below forecast↓-1.26 | $190.9M | $189.4M |
| Feb 23, 2026 | -- | -0.70 | -0.71 | $193.4M | $194.7M |
| Nov 3, 2025 | -- | -0.82 | -0.94 | $191.3M | $171M |
| Aug 4, 2025 | -- | -1.00 | -0.92 | $140M | $150M |
| May 5, 2025 | -- | -1.26 | -1.22 | $119.2M | $121.5M |
| Feb 18, 2025 | -- | -1.00 | Below forecast↓-1.54 | $118.1M | $118.8M |
| Nov 12, 2024 | -- | -1.38 | -1.34 | $98.4M | $104.8M |
| Aug 5, 2024 | -- | -1.30 | Below forecast↓-1.67 | $86.9M | $87.2M |
| May 6, 2024 | -- | -1.20 | -1.09 | $86.7M | $75M |
| Feb 20, 2024 | -- | -1.21 | Below forecast↓-2.08 | $69.2M | $71.5M |
| Nov 6, 2023 | -- | -1.24 | -1.32 | $55.8M | $57.8M |
| Aug 7, 2023 | -- | -1.24 | Below forecast↓-1.54 | $40.9M | $46.7M |
| May 8, 2023 | -- | -1.13 | Above forecast↑-0.22 | $26.6M | $94.6M |
| Feb 27, 2023 | -- | -1.18 | -1.28 | $21.8M | $24.4M |
Original Filings (SEC)
10-Q2026-08-10 ↗
8-K2026-08-10 ↗
8-K2026-07-15 ↗
8-K2026-06-09 ↗
8-K2026-06-09 ↗
8-K2026-06-03 ↗
10-Q2026-05-04 ↗
8-K2026-05-04 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
